Barrier-enforcing measures as treatment principle in allergic rhinitis: a systematic review

Andersson, Morgan; Greiff, Lennart; Ojeda, Pedro; Wollmer, Per

doi:10.1185/03007995.2014.882299

Cited by 16 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few years, the incidence and severity of AR in developed countries has gradually increased and AR has become a serious public health problem (4,31). Although some progress has been made in the treatment of AR, the therapeutic effect is still unsatisfactory (5)(6)(7)(8). Therefore, finding new and effective methods and targets for the treatment of AR is essential.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF‑κB pathway

Shu

Zhu

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

The present study investigated the underlying mechanisms and effects of toll-like receptor 4 (TLR4) on a mouse model of allergic rhinitis (AR). An ovalbumin (OVA)-induced mouse model of AR was treated with TLR4-short hairpin RNA (shRNA). Allergic symptoms were then subsequently assessed. Protein levels of OVA-specific immunoglobulin E (IgE), eosinophil cation protein (ECP), leukotriene C4 (LTC4) and prostaglandin D2 (PGD2) in mice serum and nasal lavage fluid, as well as various inflammatory cytokine mediators in mice serum, were determined by ELISA. Protein level detection was performed using reverse transcription-quantitative PCR and western blot analysis. The results revealed that TLR4 was highly expressed in the nasal mucosa of AR mice. TLR4 inhibition significantly relieved OVA-induced AR symptoms. Relief of symptoms was evidenced by a decreased frequency of sneezing and nose friction, reduced levels of OVA-specific IgE, ECP, LTC4, PGD2, less inflammatory cells and decreased levels of T-helper 2 type cytokines. In addition, the data indicated that OVA-induced activation of the NF-κB pathway was repressed by TLR4-shRNA. The results of the current study indicate that TLR4 may be a promising therapeutic target of AR.

show abstract

Section: Discussionmentioning

confidence: 99%

“…There are several commonly used AR treatments, including intranasal steroids, antihistamines, leukotriene receptor antagonists and immunotherapy (5,6). However, patients with AR always have unsatisfactory results (7). It is therefore necessary to assess novel and effective AR treatments (8).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF‑κB pathway

Shu

Zhu

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Currently, the role of the mucosal barrier integrity is gaining increasing interest among scientists, as a primary prevention of different diseases, as intestinal or respiratory disorders [ 9 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

“…The utility of these measures is also supported by recent data suggesting that the epithelium with its tight junctions is considered tight under normal conditions but it can be abnormally permeable, with a decreased presence of tight junctions, in pathogenic conditions (the “hyperpermeability hypothesis”), as allergic rhinitis [ 9 , 11 – 13 ] or rhinosinusitis [ 14 , 15 ], or also in contact with high levels of contamination (such as traffic-related air pollutants) [ 16 ]. Since epithelial barrier defects are linked with chronicity and severity of airway inflammation, restoring the barrier integrity may become a useful approach in the treatment of allergic diseases [ 13 ].…”

Section: Introductionmentioning

confidence: 89%

See 1 more Smart Citation

Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study

Servi¹,

Ranzini²,

Piqué

2017

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

BackgroundTo evaluate barrier protective properties of Rhinosectan® spray, a medical device containing xyloglucan, on nasal epithelial cells (MucilAir).MethodsMucilAir-Nasal, a three-dimensional organotypic (with different cell types) airway tissue model, was treated with the medical device Rhinosectan® (30 µL) or with controls (Rhinocort—budesonide—or saline solution). The protective barrier effects of Rhinosectan® were evaluated by: TEER (trans-epithelial electrical resistance) (preservation of tight junctions), Lucifer Yellow assay (preservation of paracellular flux) and confocal immunofluorescence microscopy (localization of tight junction proteins).ResultsExposure of MucilAir with Rhinosectan® protected cell tight junctions (increases in TEER of 13.1% vs −6.3% with saline solution after 1 h of exposure), and preserved the paracellular flux, even after exposure with pro-inflammatory compounds (TNF-α and LPS from Pseudomonas aeruginosa 10). Results of confocal immunofluorescence microscopy demonstrated that, after treatment with the pro-inflammatory mixture, Rhinosectan® produced a slight relocation of zona occludens-1 in the cytosol compartment (while Rhinocort induced expression of zona-occludens-1), maintaining the localization of occludin (similarly to negative control).ConclusionsResults of our study indicates that Rhinosectan® creates a protective physical barrier on nasal epithelial cells in vitro, allowing the avoidance of allergens and triggering factors, thus confirming the utility of this medical device in the management of nasal respiratory diseases, as rhinitis or rhinosinusitis.

show abstract

Medical devices in allergy practice

Popov

Passalacqua

González‐Díaz

et al. 2020

World Allergy Organization Journal

View full text Add to dashboard Cite

Medical devices provide people with some health benefits in terms of diagnosis, prevention, treatment, and monitoring of disease processes. Different medical specialties use varieties of medical devices more or less specific for them. Allergology is an interdisciplinary field of medical science and teaches that allergic reactions are of systemic nature but can express themselves at the level of different organs across the life cycle of an individual. Subsequently, medical devices used in allergology could be regarded as: 1) general, servicing the integral diagnostic and management principles and features of allergology, and 2) organ specific, which are shared by organ specific disciplines like pulmonology, otorhinolaryngology, dermatology, and others. The present position paper of the World Allergy Organization (WAO) is meant to be the first integral document providing structured information on medical devices in allergology used in daily routine but also needed for sophisticated diagnostic purposes and modern disease management. It is supposed to contribute to the transformation of the health care system into integrated care pathways for interrelated comorbidities.

show abstract

Barrier-enforcing measures as treatment principle in allergic rhinitis: a systematic review

Abstract: Barrier-enforcing measures as achieved by nasal administrations of cellulose powder and microemulsions, respectively, have symptom-reducing effects in allergic rhinitis.

Cited by 16 publications

References 32 publications

Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF‑κB pathway

Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF‑κB pathway

Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study

Medical devices in allergy practice

Contact Info

Product

Resources

About